Replimune Group's stock dropped about 84% between October 2025 and April 2026 after the FDA rejected its RP1 biologics license application due to unresolved study design concerns. Despite company statements suggesting progress toward approval, the FDA's complete response letter in April 2026 revealed that critical issues remained unaddressed, causing a sharp decline in share price. A securities class action lawsuit has been filed alleging the company misled investors about the drug's regulatory status. Investors who bought shares during this period may seek compensation by October 5, 2026.
Replimune Group's stock faced a severe decline of about 84% between October 2025 and April 2026 following regulatory setbacks. For readers following health-sector stocks, here is Pluang's market snapshot as of Sep 17, 2026 21:11 WIB: out of 91 priced US health-sector stocks, 59 rose and 31 fell. Notable movers include Recursion Pharmaceuticals Inc (RXRX) with a price of USD 3.37 and a 1-day change of +5.64%, Illumina, Inc. (ILMN) at USD 241.64 with a 1-day change of +5.55%, and Ginkgo Bioworks Holdings Inc (DNA) at USD 7.44 with a 1-day change of +5.38%.
The Hershey Trust Company sold 1,512 common shares under a trading plan but kept voting control through Class B shares. Hershey will report Q3 earnings on October 29, with investors focused on how price increases affected Halloween-season demand. Q2 ...
W. R. Berkley reported mixed Q3 2026 results with earnings per share of $1.17 beating estimates, but revenue fell short at $3.74 billion versus $3.82 billion expected. The company saw premium growth with gross premiums up 3% and net premiums up 1%, s...
GE Aerospace is set to report its Q3 earnings with analysts forecasting a 21.7% rise in earnings per share to $2.02 and nearly 12% revenue growth to about $12.7 billion. Despite consistently beating estimates, the stock has fallen after past reports ...
Silence Therapeutics' stock surged 125.6% to $19.58 following Merck KGaA's agreement to acquire the RNA-interference drug developer for about $1.3 billion in equity value. Merck will pay $20 per share, a 130% premium over the recent closing price. Ot...
On October 19, 2026, several stocks saw significant declines. Iambic Therapeutics dropped 31.4% but stayed just above its IPO price of $16 after raising $150 million. TCGX Acquisition fell 18.5% following its announcement of a merger with TriGemX Bio...
